Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Video of Dr. Lilge's recent webinar - 119 mins.
View:
Comment by DJDawg on Aug 25, 2021 12:09pm
As you are the scientific gury for this forum, any interesting tidbits? I got lost after a bit myself.
Comment by socksnblonds642 on Aug 25, 2021 12:48pm
Definitely look fwd to Ego and CS input on the tech side. My takeaway is that Dr Lilge and team are devising a metric to compare PDT's and that he will be releasing a paper comparing them. He said his focus has been mainly on Ruthinium based PD's lately...look fwd to seeing that The metric may be the number of photon's absorbed per cubic cm to achieve cell death. The point is to ...more  
Comment by Eoganacht on Aug 25, 2021 12:53pm
I'm no kind of scientific guru, I'm just preoccupied with dd for Theralase. Dr. Lilge is taking great pains to lay the groundwork for oncological pdt. Oncological pdt is the central focus of Theralase and the research will be invaluable if and when Theralase advances it's treatment into other cancer indications - but Dr. Lilge's work is applicable to any group that decides to ...more  
Comment by fredgoodwinson on Aug 25, 2021 1:43pm
Thanks yet again Eoganacht - just watched for the first time.Great to listen to and learn from Dr.Lilge again - it`s been too long since those AGM Presentations. Interesting that on his list of Industrial Collaborators at Theralase on p.50 was Roger (no Shawn). Also that he was at the time preparing a paper that would use a standardised basis for the comparison of Rutherium-based photosensitisers ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250